

1 SUBMITTED 11 NOV 21  
2 REVISION REQ. 12 DEC 21; REVISIONS RECD. 26 DEC 21  
3 ACCEPTED 1 FEB 22  
4 **ONLINE-FIRST: FEBRUARY 2022**  
5 **DOI: <https://doi.org/10.18295/squmj.2.2022.018>**  
6

7 **Dermatological Lesions of Cholesterol Embolization Syndrome and Kaposi**  
8 **Sarcoma Mimic Primary Systemic Vasculitis**

9 *Case Report Study*

10 **Abdulmohsen S. Alqurashi,<sup>1</sup> Mohammed H. Aly,<sup>2</sup> Abdulghaffar Mohammed,<sup>2</sup>**  
11 **Walaa A. Ahmed,<sup>1</sup> Abdullah M. Alhazmi,<sup>1</sup> Amal A. Ahmed,<sup>3</sup> Abdulrahman A.**  
12 **Alshehri,<sup>4</sup> \*Abdulrahman M. Almalki<sup>1</sup>**

13  
14 <sup>1</sup>*College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia; Departments of*  
15 <sup>2</sup>*Internal Medicine, <sup>3</sup>Histopathology and <sup>4</sup>Rheumatology, Security Forces Hospital, Makkah,*  
16 *Saudi Arabia.*

17 *\*Corresponding Author's e-mail: [amalki2023@gmail.com](mailto:amalki2023@gmail.com)*  
18

19 **Abstract**

20 Primary systemic vasculitis can present with a wide spectrum of manifestations ranging from  
21 systemic non-specific features such as fever, malaise, arthralgia, and myalgia to specific organ  
22 damage. We describe two cases of cholesterol embolization syndrome and Kaposi sarcoma  
23 mimicking primary systemic vasculitis, both of which were characterized by features such as  
24 livedo reticularis, blue toe syndrome, a brown, purpuric skin rash, and positive p-ANCA  
25 associated with Kaposi sarcoma. Establishing the right diagnosis was challenging, and thus  
26 we aim in this study to highlight the possible ways to distinguish them from primary systemic  
27 vasculitis.

28 **Keywords:** Dermatological lesions, Cholesterol embolization syndrome, Kaposi sarcoma,  
29 vasculitis mimic  
30

## 31 **Introduction**

32 Vasculitis is an inflammatory process affecting the blood vessels, causing destruction that leads  
33 to ischemia, hemorrhage, or both (1). It has a wide spectrum of manifestations ranging from  
34 systemic non-specific features such as fever and a loss of appetite or weight to specific organ  
35 damage such as kidney and/or cutaneous damage manifested by purpura nodules, purpuric  
36 urticaria, livedo reticularis, and skin ulcers (2,3). Thus, non-specific diverse manifestations can  
37 be mistaken for other conditions. We report two cases of the rare presentation of cholesterol  
38 embolization syndrome (CES) and Kaposi sarcoma (KS) mimicking vasculitis. We aim to  
39 prompt their recognition and distinguish them from vasculitis.

40

## 41 **Case presentation**

### 42 **Case One**

43 A 65-year-old man, a known case of triple coronary artery vessel disease based on a coronary  
44 angiogram performed a week before, presented to our hospital with abdominal pain and vomiting  
45 for a day. Physical examination revealed a skin rash, livedo reticularis, and the blue discoloration  
46 of the toes, which suggested blue toe syndrome (**Figure 1**). All other physical examinations were  
47 unremarkable.

48

49 The patient was admitted, and laboratory investigations showed the following results: white  
50 blood cell count of  $14/\text{mm}^3$  with neutrophils 53%, eosinophile 9%, and lymphocytes 32%;  
51 hemoglobin 11.1 g/dL; platelets  $144 \times 10^3/\text{mm}^3$ ; erythrocyte sedimentation rate 32 mm/h; C-  
52 reactive protein 35 mg/L; creatinine 2.4 mg/dL; and urea 43 mg/dL; aspartate aminotransferase  
53 36 U/L (normal range, 10–41 U/L); alanine aminotransferase 31 U/L (normal range, 10–40 U/L);  
54 total cholesterol 209 mg/dL; high-density lipoprotein 42 mg/dL; low-density lipoprotein 138  
55 mg/dL; triglyceride 140 mg/dL; serum iron 64lg/dL (normal range, 50–140 lg/dL); serum ferritin  
56 138 ng/ml (normal range, 15–300 ng/ml); transferrin iron binding capacity 238 lg/dL (normal  
57 range, 130–350 lg/dl). The urinary protein level was 600 mg/dL and the microscopic urinary  
58 examination was negative for cells and casts. Serological testing for anti-nuclear antibodies,  
59 anti-neutrophil cytoplasmic antibodies, hepatitis C virus, and hepatitis B surface antigen all were  
60 negative.

61 On abdominal ultrasound, both kidneys were within normal size with no other remarkable  
62 findings. Transthoracic echocardiography showed the left ventricle normal in size with an  
63 ejection fraction of 57%, no intramural thrombus, or any evidence of infective endocarditis.  
64 Multiple biopsies of the affected skin and kidney were arranged but, unfortunately, were refused  
65 by the patient.

66

## 67 **Case Two**

68 An 86-year-old woman presented with intermittent fever, dyspnea, a dry cough, and a loss of  
69 weight for two months. Physical examination revealed a bilateral brown/purple ill-demarcated  
70 plaque over the tibia and dorsum of the feet (**Figure 2**). Laboratory investigation revealed mild  
71 thrombocytopenia ( $124 \times 10^3/\text{mm}^3$ ), anemia (10.6 g/dL), high erythrocyte sedimentation rate (55  
72 mm/h), and high C-reactive protein (42 mg/L); serological testing was positive for perinuclear  
73 anti-neutrophil cytoplasmic antibodies (p-ANCA), and enzyme-linked immunoassay testing  
74 revealed positive anti-myeloperoxidase with a titre of 512 AAU/ml (normal: 0-150 AAU/ml),  
75 and negative for anti-proteinase 3. All other investigations were within the normal range  
76 including coagulation profile, renal function, and HBV and HCV testing. Multiple biopsies of  
77 lesions were taken and these showed areas of hemorrhage, a vague network of connecting  
78 channels, and positive human herpesvirus-8 on immunohistostaining (**Figure 3**), which is  
79 consistent with KS. Human immunodeficiency virus testing was carried out and was negative.

80

## 81 **Declaration of patient consent**

82 The authors certify that they obtained all appropriate patient consent forms. In the form, patients  
83 provided consent for their images and other clinical information to be reported in the journal.  
84 They understand that their names and initials will not be published, and due efforts will be made  
85 to conceal their identity, but anonymity cannot be guaranteed.

86

## 87 **Discussion**

88 Multiple conditions can injure or occlude the blood vessels and mimic the clinical picture of  
89 vasculitis. The location and size of the affected vessel determine the clinical manifestations of  
90 the vascular injury more than the underlying cause. For example, damage to small cutaneous  
91 vessels is manifested by palpable purpura, urticaria, livedo reticularis, papulovesicular lesions,

92 and nodules. Similarly, damage can arise in the heart, kidney, gastrointestinal tract, and brain (4).  
93 These diseases are not necessarily associated with blood wall inflammation. However, they  
94 might have the same findings of vasculitis in clinical, laboratory, radiographic and/or pathologic  
95 settings, which leads to diagnostic confusion (5).

96  
97 CES is a great mimic, which makes it confusing for the diagnosis of vasculitis. A purpuric rash,  
98 livedo reticularis, myalgia, and acute renal failure are some of the symptoms that can occur.  
99 Cholesterol emboli can complicate cardiac catheterization and arteriography; moreover, this can  
100 happen spontaneously, even in individuals who have never suffered previous vascular disease  
101 (6). In our first case, the patient developed manifestations that mimic the typical features of  
102 Churg–Strauss vasculitis such as livedo reticularis, purpura, skin ulceration, and infarction and  
103 eosinophilia (6).

104  
105 Moreover, renal failure can be found in both syndromes. While this can mask diagnosis, multiple  
106 biopsies of affected sites (skin, kidney, and muscle) can identify the characteristics of CES,  
107 namely, occluded small arteries and arterioles characterized by a lance-shaped cleft (dissolution  
108 of cholesterol crystals) (7). Unfortunately, our patient refused the biopsy and the diagnosis was  
109 made based on clinical pictures.

110  
111 The other case is KS mimicking vasculitis at the time of presentation. KS is a malignant tumor  
112 that affects immunocompromised patients such as those infected with HIV, those who receive  
113 immunosuppressants drugs, and those with congenital causes (8). KS skin lesions manifest as  
114 red, purple, and brownish patches and dots, which can be misidentified as malignant or vascular  
115 lesions in some phases due to the rise in superficial vascularity (9).

116  
117 p-ANCA, an important marker for ANCA-associated vasculitis, has been found to be 91%  
118 specific (10). The clinical pictures of a brown, purpuric rash on the lower limbs, as in our case, in  
119 addition to positive p-ANCA are highly suggestive of vasculitis. A previously reported case of  
120 KS and positive p-ANCA was due to existing vasculitis (11). In fact, the patient developed KS  
121 after receiving an immunosuppression agent to treat vasculitis. But our case is unique in that p-  
122 ANCA was positive at the time of presentation with no existent vasculitis. However, the

123 possibility of incidental finding or our patient could develop vasculitis later is possible. To the  
124 best of our knowledge, there are no reported cases in the literature of KS associated with positive  
125 p-ANCA with no existing vasculitis. Further studies, which take these variables into account,  
126 will need to be undertaken.

127

## 128 **Conclusion**

129 Many conditions can mimic the clinical and laboratory features of vasculitis. Herein, we present  
130 two cases of CES and KS as mimics that might delay the correct diagnosis. However, a previous  
131 history of angiography catheterization and biopsy would cut doubt with certainty. This study  
132 aims to raise awareness of the possible differential diagnoses of vasculitis. Further studies are  
133 needed to investigate the relation between positive p-ANCA in patients and KS.

134

## 135 **Acknowledgement**

136 The authors appreciate the Research Code Team (RCT) at Umm Al-Qura University (UQU) for their  
137 valuable contribution and efforts in supervising this research project.

138

## 139 **Authors' Contribution**

140 ASA is responsible for the majority of the work. AMAm drafted the manuscript and handled the  
141 designing and formatting. WAA and AMAh collected the clinical information and wrote the initial  
142 manuscript. AmAA provided the histopathology results. AMAm formulated the abstract. MHA, AM, and  
143 AbAA were the treating physicians. All authors approved the final version of the manuscript.

144

## 145 **References**

- 146 1. Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. *Am J Clin Dermatol.*  
147 2008;9(2):71–92.
- 148 2. Shavit E, Alavi A, Sibbald RG. Vasculitis—What Do We Have to Know? A Review of  
149 Literature. *Int J Low Extrem Wounds [Internet].* 2018;17(4):218–26. Available from:  
150 <https://doi.org/10.1177/1534734618804982>
- 151 3. Mishra A, Iyadurai R, George A, Rajdurai E, Surekha V. Etiological and  
152 clinicopathological study of secondary small vessel vasculitis in elderly: A case series of  
153 12 patients. *J Fam Med Prim Care.* 2017;6(1):106.
- 154 4. Sack KE. The difficulties of differentiating vasculitis from its mimics. *Cleve Clin J Med.*

- 155 1998;65(10):550–2.
- 156 5. Molloy ES, Langford CA. Vasculitis mimics. *Curr Opin Rheumatol*. 2008;20(1):29–34.
- 157 6. Fegan CD. Lesson of the Week: Any Questions. *Bmj*. 1995;310(6979):580.
- 158 7. Maningding E, Kermani TA. Mimics of vasculitis. *Rheumatol (United Kingdom)*.
- 159 2021;60(1):34–47.
- 160 8. Vangipuram R, Tyring SK. Epidemiology of Kaposi sarcoma: review and description of
- 161 the nonepidemic variant. *Int J Dermatol*. 2019;58(5):538–42.
- 162 9. Marušić Z, Billings SD. Histopathology of Spindle Cell Vascular Tumors. *Surg Pathol*
- 163 *Clin*. 2017 Jun;10(2):345–66.
- 164 10. Guchelaar NAD, Waling MM, Adhin AA, van Daele PLA, Schreurs MWJ, Rombach SM.
- 165 The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of
- 166 ANCA-associated vasculitis, a systematic review and meta-analysis. *Autoimmun Rev*.
- 167 2021 Jan;20(1):102716.
- 168 11. Fatma L Ben, Rais L, Mebazza A, Azzouz H, Beji S, Krid M, et al. Saudi Journal of
- 169 Kidney Diseases and Transplantation. *Saudi J Kidney Dis Transplant [Internet]*. 2013
- 170 [cited 2021 Nov 9];24(6):1199. Available from:
- 171 [https://www.sjkdt.org/article.asp?issn=1319-](https://www.sjkdt.org/article.asp?issn=1319-2442;year=2013;volume=24;issue=6;spage=1199;epage=1202;aulast=Fatma)
- 172 [2442;year=2013;volume=24;issue=6;spage=1199;epage=1202;aulast=Fatma](https://www.sjkdt.org/article.asp?issn=1319-2442;year=2013;volume=24;issue=6;spage=1199;epage=1202;aulast=Fatma)
- 173



174

175 **Figure 1:** the dermatological findings at presentation in case 1


176



177

178 **Figure 2:** the dermatological findings at presentation in case 2.

179



180

181 **Figure 3: A:** shows areas of hemorrhage and vague network of connecting channels, dilated  
182 channels lined by small hyperchromatic nuclei **B:** HHV-8 immunohistostaining shows positive  
183 granular nuclear staining